You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Shingrix Logo

Product menu

Doctor speaking to a patient

Ready to vaccinate with SHINGRIX (herpes zoster vaccine, recombinant, adjuvanted)?

Get the information you need to administer SHINGRIX to adults 50 years of age and older with confidence.1

Reconstitution Instructions for SHINGRIX

This video will guide you through the reconstitution process for SHINGRIX.

SHINGRIX prescribing information

POM. Further information available from GlaxoSmithKline, 12 Riverwalk, Citywest, Business Campus, Dublin 24. Tel: 01-4955000.

PM-IE-SGX-WCNT-220001 | Date of Preparation: May 2023

PREV
NEXT

Dosing and administration

Schedule

SHINGRIX is given as a 2-dose schedule

For adults 50 years of age and older, the second dose should be administered 2 months after the first dose. If flexibility is necessary, the second dose can be administered between 2–6 months after the first dose.1

two syringes showing a two dose schedule

SHINGRIX co-administration

SHINGRIX can be co-administered with several different vaccines. For more information on co-administration of SHINGRIX and other vaccines, please consult the SHINGRIX Summary of Product Characteristics.1

Thermometer

SHINGRIX should be refrigerated. DO NOT FREEZE

Store in a refrigerator 2°C – 8°C.1

After reconstitution, the vaccine should be used immediately; if this is not possible, the vaccine should be stored in a refrigerator (2°C – 8°C). If not used within 6 hours, it should be discarded.1

Two vials

SHINGRIX is supplied as 2 vials for reconstitution and is for intramuscular injection only, preferably in the deltoid muscle1

The vial containing the powder (antigen) and the vial containing the suspension (adjuvant) MUST be reconstituted prior to administration.1

For further safety information on SHINGRIX including a full list of adverse reactions reported during post-marketing surveillance, please consult the Summary of Product Characteristics.1

Making it part of your routine

red exclamation mark in a red triangle

Explain their risk of shingles:

1. Age-related decline in immunity puts patients 50 years of age and older at an increased risk of developing shingles.3,4

2. Shingles is a painful disease that can have serious and long-lasting complications.4

two boxes numbered 1 and 2 interlinked

Explain the benefit of protection from both doses:

1. Dosing and administration: It takes 2 doses to help protect adults 50 years of age and older with SHINGRIX.1

2. SHINGRIX is given as a two-dose schedule, an initial dose followed by a second dose 2 months later. If flexibility is necessary, the second dose can be administered between 2–6 months after the first dose.1

messsage icon in red

Tell them what to expect:

1. The specific side effects they are likely to encounter.

2. How long any side effects may last.

For further safety information on SHINGRIX including a full list of adverse reactions reported during post-marketing surveillance, please consult the Summary of Product Characteristics.1

SHINGRIX vaccine MUST be reconstituted prior to administration.1

Ensuring two-dose schedule completion

Schedule in red

Schedule the follow-up promptly and encourage reminders:

SHINGRIX is given as a 2-dose schedule, an initial dose followed by a second dose 2 months later.1

Once a date is set for their second dose, advise your patients to place a reminder in their personal calendar.
Additionally, use a telephone call to remind patients of their upcoming appointment.

Ringing phone in red

GSK resources

Support your patients and practice with healthcare resources on our resources page (delivery is free on all orders).

For further safety information on SHINGRIX including a full list of adverse reactions reported during post-marketing surveillance, please consult the Summary of Product Characteristics.1

Learn more about SHINGRIX

>90% Efficacy against Herpes Zoster icon

How efficacious is SHINGRIX?

SHINGRIX demonstrated >90% efficacy against shingles in adults 50 years of age and older based on pooled data from two large, phase 3 randomised controlled trials.1,5,6

VIEW EFFICACY DATA

patient profiles icon

Who can benefit from SHINGRIX?

There is a 1 in 3 lifetime risk of developing shingles.8 Age-related decline in immunity puts patients 50 years of age and older at an increased risk of developing shingles.2,3

View Patient Profiles

safety white cross red circle

Learn more about the safety profile of SHINGRIX.

The majority of local and systemic adverse reactions were mild to moderate and transient, based on two large, phase 3 randomised controlled trials. Reactions reported as severe lasted 1 to 2 days.1,5,6

Explore Safety Data

References

  1. SHINGRIX Summary of Product Characteristics. Available from: https://www.medicines.ie/medicines/shingrix-powder-and-suspension-for-suspension-for-injection-herpes-zoster-vaccine-recombinant-adjuvanted--35192/spc. Last Accessed May 2023.
  2. Gauthier et al. Epidemiology and costs of herpes zoster and postherpetic neuralgia in the United Kingdom . Epidemiol infecti. 2009 137 38-472.
  3. Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med. 2007 Mar;356 (13):1338-43.
  4. UK NICE Clinical Knowledge Summaries. What are the complications? October 2020. Accessed May 2021.
  5. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015 May;372 (22):2087-96.
  6. Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang S-J, Diez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016 Sep;375 (11):1019-32.
  7. NIAC. Chapter 23 Varicella-Zoster. 2022 October. Available on https://rcpi.access.preservica.com/uncategorized/IO_e74b6219-7108-4d6f-b099-0db8ef746acf/ Last Accessed: May 2023.
  8. Public Health England Green Book. Immunisation Procedures Chapter 4. Jun 2012.

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

SHINGRIX is owned by or licensed to the GSK group of companies. © 2022 GSK group of companies or its licensor. Trade marks are owned by or licensed to the GSK group of companies.

PM-IE-SGX-WCNT-210007 | Date of Preparation: May 2023